Syncona gains as Beacon gene therapy trial meets endpoint
Shares of British healthcare investment firm Syncona rose 6% to 118 pence after its portfolio company Beacon Therapeutics' Phase II/III VISTA trial met the FDA-endorsed primary endpoint for gene therapy laru-zova. The response rate was 31% in the high-dose arm and 24.1% in the low-dose arm, supporting plans for regulat